ArticlePloS one2025
Association of CSF visinin-like protein 1 levels with cerebral glucose metabolism among older adults.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modulating Cerebrospinal Fluid Composition in Neurodegenerative Processes: Modern Drug Delivery and Clearance Strategies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCSF visinin-like protein 1 (VILIP-1) levels have exhibited potential utility as a marker of neuronal damage and are increased in Alzheimer's disease (AD). The levels of CSF VILIP-1 have been associated with memory decline and hippocampal atrophy, while no studies have investigated the association between CSF VILIP-1 levels and cerebral glucose metabolism among older adults.
methodsStudy participants had available baseline CSF VILIP-1 data and more than two assessments of 18-fluorodeoxyglucose positron emission tomography ([18F] FDG-PET) brain imaging. Linear mixed-effects models were used to examine the association between baseline CSF VILIP-1 levels and longitudinal changes in FDG-PET over time. Models were performed separately for the cognitively unimpaired (CU) and cognitively impaired (CI) participants.
resultsAmong CU older adults, higher CSF VILIP-1 levels were marginally associated with a faster reduction in cerebral glucose metabolism. In CI older adults, CSF VILIP-1 levels were significantly associated with a faster reduction in cerebral glucose metabolism.
conclusionThese results provide novel insights into the relationship between neuronal injury and cerebral glucose metabolism, highlighting the potential of CSF VILIP-1 as a biomarker for monitoring and predicting the progression of neurodegenerative processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.